drugset / Trial / NCT02670018

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone

NCT02670018

Phase 1 Unknown 25 enrolled LG Life Sciences
RandomizedCrossoverOpen-labelTreatment

Summary

A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of the Combination of Gemigliptin/Metformin HCl Sustained Release 50/2000 mg(25/1000 mg x 2 tablets) in Comparison to Each Component Gemigliptin 50 mg and Metformin HCl Extended Release 2000 mg (1000 mg x 2 tablets) Administered in Healthy Male Volunteers.

Timeline

Start
2015-08
Primary completion
2015-12
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gemigliptin Small molecule 25 mg
Comparator Gemigliptin Small molecule 50 mg
Comparator Metformin Small molecule 2000 mg

Indications

No indication recorded.